Gerald Mosely

Dr. Gerald Mosely possesses 25 years of experience in the pharmaceutical industry. Gerald Mosely, PhD, currently serves as acting Chief Commercial Officer at Arbor Vita Corporation in Fremont, California. He previously held sales, marketing, and operational roles at major pharmaceutical companies, such as GlaxoSmithKline plc. Prior to his professional pursuits, Dr. Gerald Mosely studied biology at Loma Linda University in Riverside, California, graduating with a Bachelor of Science. He then enrolled in the Experimental Pathology program at the University of Washington, Seattle, receiving a Doctor of Philosophy in 1986. During his PhD studies, Dr. Gerald Mosely published research on a human melanoma-associated antigen. His doctoral dissertation focused on identifying tumor antigens and understanding their nature. In 1986, Dr. Gerald Mosely began his professional career as a Hospital Sales Representative for Acute Care Products at SmithKline & French (now GlaxoSmithKline). Dr. Mosely excelled in pharmaceutical sales and rose to the position of District Sales Manager before changing directions in order to focus on marketing and operations. Dr. Mosely remained with GlaxoSmithKline until 2007, fulfilling a number of roles ranging from Product Marketing of Anti-Infective Products to International Marketing Manager and Commercial Operations Director. While executing these roles, Dr. Mosely lived in locations around the world, including Philadelphia, London, and Kuala Lumpur, Malaysia. In 2000, Gerald Mosely earned a promotion to Regional Vice President for Southern California and, in 2003, to Vice President of Sales for the Western Sector. In 2007, Gerald Mosely, PhD, left GlaxoSmithKline to accept the position of General Manager for Global Anesthesia & Critical Care at Baxter Healthcare International. He served in this position until 2009, when he accepted his current role. At Arbor Vita Corporation, Dr. Gerald Mosely leads the transformation of the organization from R&D; to include commercial operations. The firm focuses on developing diagnostic and therapuetic products utilizing a PDZ/proteomics based platform, leading with a cervical cancer diagnostic. Dr. Gerald Mosely also helped to commercialize the AVantage H5N1 rapid test that was cleared by the Food and Drug Administration (FDA) in April 2009.